Achieve Life Sciences to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 ivps42019-03-15T13:39:47-05:00March 18th, 2019|Press Release| Read More
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update ivps42019-03-13T17:01:42-05:00March 14th, 2019|Press Release| Read More
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019 ivps42019-03-01T17:18:29-05:00March 5th, 2019|Press Release| Read More
Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting ivps42019-02-19T17:33:44-05:00February 22nd, 2019|Press Release| Read More
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation ivps42019-02-19T15:59:12-05:00February 20th, 2019|Press Release| Read More
Achieve Announces Update on Cytisinicline Clinical Development Program ivps42018-12-17T17:56:19-05:00December 18th, 2018|Press Release| Read More
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update ivps42018-11-06T04:15:59-05:00November 7th, 2018|Press Release| Read More
Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018 ivps42018-10-29T16:03:57-05:00October 31st, 2018|Press Release| Read More
Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation ivps42018-10-29T16:55:13-05:00October 30th, 2018|Press Release| Read More
Achieve Announces Pricing of $5.6 Million Registered Direct Offering ivps42018-10-01T08:50:52-05:00October 1st, 2018|Press Release| Read More